Skip to main content

22-02-2019 | Adalimumab biosimilar | News


EMA gives nod to two adalimumab biosimilars

medwireNews: The Committee for Medicinal Products for Human Use has recommended two new adalimumab biosimilars for approval in Europe.

The two agents – marketed under the brand names of Kromeya and Idacio – are recommended for the same indications as adalimumab, namely rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and axial spondyloarthritis, as well as other inflammatory diseases including psoriasis, Crohn’s disease, and ulcerative colitis.

As with the reference product, the EMA recommends that treatment with the biosimilars should be supervised by physicians experienced in the management of these conditions.

The agents will be available as a solution for injection containing 40 mg of the tumor necrosis factor inhibitor in a prefilled syringe or pen.

By Claire Barnard

medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group

See also:

Related topics

More on this topic

13-12-2017 | Biosimilars | Feature | Article

Biosimilars: The story so far

Repurposing rheumatology drugs for COVID-19

Experts discuss the rationale, data on different agents, and the potential impact on rheumatology practice.

  • » Featuring insights from the COVID-19 Global Rheumatology Alliance, EULAR, and the Lupus Foundation of America
Image Credits